Alloderm

Alloderm is an ECM Biomaterial marketed by LifeCell Corporation that is used in reconstructive and dental surgeries; it is derived from skin taken from donated cadavers.[1][2] Alloderm has been used to reconstruct breasts experimentally after breast cancer surgery.[3] Alloderm has been used as a gingival graft in periodontics; when using Alloderm, there is no need for a palatal donor site [4] Alloderm has been used for abdominal hernia repair.[5] Alloderm has been used in otorhinolaryngology as implants to rebuild resected turbinates in the treatment of Empty nose syndrome.[6]

Lifecell the marketer of Alloderm was founded in 1986 in Texas; sales of Alloderm were $93,000 in 1994 shortly after the product launched and were $2 million by 1996.[7] There was a major voluntary recall of Alloderm in 2005 due to problems at a tissue supplier, Biomedical Tissue Services.[8] Sales were $146M in 2006, a 50% increase over the prior year.[2] Sales reached $167 million by 2007, and in 2008 LifeCell was acquired by Kinetic Concepts for $1.7B.[9]

References

  1. ↑ Naomi Freundlich for the New York Times. March 16, 2003 All of Me
  2. 1 2 Kerry Howley for the LA Times. March 6, 2007 Big business in body parts
  3. ↑ Salzberg, C. Andrew (2006-07-01). "Nonexpansive immediate breast reconstruction using human acellular tissue matrix graft (AlloDerm)". Annals of Plastic Surgery. 57 (1): 1–5. ISSN 0148-7043. PMID 16799299. doi:10.1097/01.sap.0000214873.13102.9f.
  4. ↑ Hirsch A, Goldstein M, Goultschin J, Boyan BD, Schwartz Z (2005). "A 2-year follow-up of root coverage using sub-pedicle acellular dermal matrix allografts and subepithelial connective tissue autografts". Journal of Periodontology. 76 (8): 1323–8. PMID 16101365. doi:10.1902/jop.2005.76.8.1323.
  5. ↑ Misra, S.; Raj, P. K.; Tarr, S. M.; Treat, R. C. (2008-06-01). "Results of AlloDerm use in abdominal hernia repair". Hernia: The Journal of Hernias and Abdominal Wall Surgery. 12 (3): 247–250. ISSN 1265-4906. PMID 18209948. doi:10.1007/s10029-007-0319-z.
  6. ↑ Leong SC. The clinical efficacy of surgical interventions for empty nose syndrome: A systematic review. Laryngoscope. 2015 Jul;125(7):1557-62. Review. PMID 25647010
  7. ↑ Frank Bass for the Wall Street Journal. June 25, 1997 For Patient Investors, LifeCell May Yet Deliver on Its Promise
  8. ↑ Dow Jones Newswires in the Wall Street Journal. Oct. 7, 2005 LifeCell Issues Voluntary Recall, Withdraws Financial Guidance
  9. ↑ Kevin Kingsbury for the Wall Street Journal. April 8, 2008 Kinetic to Acquire LifeCell


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.